Monoceros Biosystems
Monoceros Biosystems is a leading bioinformatics service provider dedicated to advancing genomics and bioinformatics. They aim to improve the diagnosis and treatment of diseases, including cancer, by offering top-tier informatics services and innovative solutions. The company has extensive experience supporting all stages of drug discovery across many therapeutic areas and modalities, utilizing a cloud-based AI-enabled platform and a diversified team of dedicated analysts. Monoceros Biosystems collaborates with industry leaders and academic institutions to push the boundaries of cancer diagnostics and drug development.
Industries
Nr. of Employees
small (1-50)
Products
Bioinformatics Services
Provides support throughout the drug development process, including target identification, model selection, PD and MoA studies, translational biomarkers, patient selection strategies, clinical development support, indications discovery, and drug repositioning.
Therapeutic Area Expertise
Offers expertise in various therapeutic areas such as oncology, immunology, neurology, ophthalmology, infectious disease, fibrosis, metabolic disease, respiratory, and rare diseases.
Therapeutic Modalities Expertise
Specializes in therapeutic modalities including small molecules, antibodies, peptides, oligonucleotide therapeutics, RNA and gene therapy, and vaccines.
AI-Enabled Platform
Utilizes a cloud-based artificial intelligence-enabled platform to provide bioinformatics solutions and access to key public datasets.
Experiment Design and Data Interpretation
Assists with experimental design and data interpretation to optimize the value extracted from experiments and support rational decision-making.
Bioinformatics Services
Provides support throughout the drug development process, including target identification, model selection, PD and MoA studies, translational biomarkers, patient selection strategies, clinical development support, indications discovery, and drug repositioning.
Therapeutic Area Expertise
Offers expertise in various therapeutic areas such as oncology, immunology, neurology, ophthalmology, infectious disease, fibrosis, metabolic disease, respiratory, and rare diseases.
Therapeutic Modalities Expertise
Specializes in therapeutic modalities including small molecules, antibodies, peptides, oligonucleotide therapeutics, RNA and gene therapy, and vaccines.
AI-Enabled Platform
Utilizes a cloud-based artificial intelligence-enabled platform to provide bioinformatics solutions and access to key public datasets.
Experiment Design and Data Interpretation
Assists with experimental design and data interpretation to optimize the value extracted from experiments and support rational decision-making.
Services
Consulting and delivery of bioinformatics analyses across target identification, biomarker discovery, assay design, and clinical support for biotech and pharmaceutical clients.
Platform-based delivery of AI-enabled analytics with integrated public datasets to accelerate genomic analyses.
Partnering with diagnostics providers to provide genomics and bioinformatics analyses relevant to blood-based cancer detection and monitoring.
Consulting and delivery of bioinformatics analyses across target identification, biomarker discovery, assay design, and clinical support for biotech and pharmaceutical clients.
Platform-based delivery of AI-enabled analytics with integrated public datasets to accelerate genomic analyses.
Partnering with diagnostics providers to provide genomics and bioinformatics analyses relevant to blood-based cancer detection and monitoring.
Expertise Areas
- Bioinformatics for drug discovery
- Next-generation sequencing analysis
- Single-cell and multi-omics integration
- Cancer genomics and translational analytics
Key Technologies
- Next-generation sequencing (NGS)
- Single-cell sequencing
- Multi-omics integration
- Genome annotation pipelines
News & Updates
A strategic partnership with SeekIn to revolutionize blood cancer testing using genomics and bioinformatics.
Announcement of Regan Lohman joining the board, bringing extensive finance and operational expertise.
Announcement of Jonathan Spier joining the board, with over 20 years of experience in building leading companies.
Research collaboration with Mirati Therapeutics on a novel cancer drug.
An article discussing industry guidelines for off-target risk assessment in oligonucleotide therapeutics.
A strategic partnership with SeekIn to revolutionize blood cancer testing using genomics and bioinformatics.
Announcement of Regan Lohman joining the board, bringing extensive finance and operational expertise.
Announcement of Jonathan Spier joining the board, with over 20 years of experience in building leading companies.
Research collaboration with Mirati Therapeutics on a novel cancer drug.
An article discussing industry guidelines for off-target risk assessment in oligonucleotide therapeutics.